/
KNSA
$62.18+$2.98 (+5.03%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$4.6B
77M shares
52-week range
$26.27 – $63.77
96% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.30%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$48.25
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $38.5M | $220.2M | $270.3M | $423.2M | $677.6M |
| Cost of revenue | $286.0K | $3.3M | $3.8M | $9.1M | $22.9M | $56.5M | $60.9M | $307.4M |
| Gross profit | −$286.0K | −$3.3M | −$3.8M | $29.4M | $197.3M | $213.7M | $362.3M | $370.1M |
| Gross margin | — | — | — | 76.4% | 89.6% | 79.1% | 85.6% | 54.6% |
| R&D | $86.6M | $132.9M | $109.6M | $99.3M | $65.5M | $76.1M | $111.6M | $96.9M |
| Operating income | −$108.2M | −$170.0M | −$157.4M | −$156.6M | $9.8M | −$25.2M | −$45.6M | $77.2M |
| EBITDA | −$107.9M | −$160.6M | −$152.4M | −$154.2M | $13.4M | −$14.3M | −$34.5M | $90.4M |
| Net income | −$103.2M | −$161.9M | −$161.4M | −$157.9M | $183.4M | $14.1M | −$43.2M | $59.0M |
| Net margin | — | — | — | -409.7% | 83.3% | 5.2% | -10.2% | 8.7% |
| EPS (diluted) | -3.49 | -2.99 | -2.61 | -2.30 | 2.60 | 0.20 | -0.60 | 0.75 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $939M | $1.37 | $1.27–$1.50 | 4 |
| 2027 | $1.1B | $1.91 | $1.41–$2.29 | 4 |
| 2028 | $1.3B | $2.50 | $1.46–$3.09 | 6 |
| 2029 | $1.4B | $2.96 | $2.92–$2.99 | 4 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
www.kiniksa.com- Employees
- 366
- IPO / List date
- May 24, 2018
- HQ
- LONDON
Held by traders on TradeandTell
No one on the platform currently holds KNSA.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in KNSA as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded KNSA yet.
